1. Home
  2. GNPX vs GV Comparison

GNPX vs GV Comparison

Compare GNPX & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • GV
  • Stock Information
  • Founded
  • GNPX 2009
  • GV 2013
  • Country
  • GNPX United States
  • GV Canada
  • Employees
  • GNPX N/A
  • GV N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • GV Other Consumer Services
  • Sector
  • GNPX Health Care
  • GV Real Estate
  • Exchange
  • GNPX Nasdaq
  • GV Nasdaq
  • Market Cap
  • GNPX 7.5M
  • GV 7.8M
  • IPO Year
  • GNPX 2018
  • GV 2022
  • Fundamental
  • Price
  • GNPX $0.29
  • GV $2.09
  • Analyst Decision
  • GNPX
  • GV
  • Analyst Count
  • GNPX 0
  • GV 0
  • Target Price
  • GNPX N/A
  • GV N/A
  • AVG Volume (30 Days)
  • GNPX 1.8M
  • GV 71.3K
  • Earning Date
  • GNPX 05-12-2025
  • GV 06-17-2025
  • Dividend Yield
  • GNPX N/A
  • GV N/A
  • EPS Growth
  • GNPX N/A
  • GV N/A
  • EPS
  • GNPX N/A
  • GV N/A
  • Revenue
  • GNPX N/A
  • GV $7,773,905.00
  • Revenue This Year
  • GNPX N/A
  • GV N/A
  • Revenue Next Year
  • GNPX N/A
  • GV N/A
  • P/E Ratio
  • GNPX N/A
  • GV N/A
  • Revenue Growth
  • GNPX N/A
  • GV N/A
  • 52 Week Low
  • GNPX $0.22
  • GV $1.00
  • 52 Week High
  • GNPX $3.97
  • GV $9.60
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 50.37
  • GV 50.62
  • Support Level
  • GNPX $0.26
  • GV $2.03
  • Resistance Level
  • GNPX $0.37
  • GV $2.15
  • Average True Range (ATR)
  • GNPX 0.04
  • GV 0.16
  • MACD
  • GNPX 0.00
  • GV 0.03
  • Stochastic Oscillator
  • GNPX 35.04
  • GV 47.90

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: